Methylene Blue for the Prevention of Hypotension During Hemodialysis
Methylene Blue for the Prevention of Hypotension During Hemodialysis: a Randomized Open Label Trial
Federal University of São Paulo
260 participants
Oct 21, 2021
INTERVENTIONAL
Conditions
Summary
Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.
Eligibility
Inclusion Criteria4
- Patient or legal representative accepted trial enrollment
- Age above 18 years
- Chronic or acute kidney injury in need for renal replacement therapy
- Blood pressure lower than 100 mmHg or in use of any vasopressor
Exclusion Criteria9
- Pregnancy
- Death considered imminent in the next 24 hours
- Patients not on full code status
- Hypertensive patients where dialysis was indicated to remove fluids
- Known allergy to methylene blue
- Known glucose-6-phosphate deficiency
- Previously enrolled in the trial
- Acute coronary Syndrome
- Domiciliary nitrate use
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
Usual care during renal replacement therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05092165